InvestorsHub Logo
Followers 62
Posts 7582
Boards Moderated 1
Alias Born 01/02/2003

Re: Number sleven post# 386114

Friday, 08/12/2022 7:46:29 PM

Friday, August 12, 2022 7:46:29 PM

Post# of 427308
Nsleven, Your logic seems reasonable to me...The chemistry of MD2119 is different from that of Vascepa...as is the dosing schedule of once a day vs four times a day...as well as the difference in the levels of EPA in the plasma produced by the two meds....If the Generics decide to market MD2119 "at risk" despite Amarin's patents, IMHO they could lose a lot more cash than they could earn from their infringement.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News